Federal contractor · AUSTIN, TX

VIA THERAPEUTICS, LLC

No contract obligations recorded for VIA THERAPEUTICS, LLC in FY2026. Since FY2018: $5.4M. It also received $2.5M in federal grants and other assistance in FY2026.

Obligations · FY2026
$0
New awards
0
Sole-source
—
Single offer
—
UEI
YHRZATLXKL46
Small business
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 599.9KFY2018
  2. 3MFY2020
  3. 300KFY2021
  4. 0FY2022
  5. 1.5MFY2023

Top buying agencies

Obligations in FY2026.

No contract obligations recorded for VIA THERAPEUTICS, LLC in FY2026.

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

VIA THERAPEUTICS, LLC received $2.5M in federal assistance in FY2026, on 8 actions (3 new awards), +56% vs FY2025. Its largest program was 93.855 · Allergy and Infectious Diseases Research ($1.3M).

Assistance · FY2026
$2.5M
New awards
3
Actions
8
Since FY2021
$5M

Assistance by fiscal year

  1. 508.3KFY2021
  2. -137.7FY2022
  3. 0FY2023
  4. 300KFY2024
  5. 1.6MFY2025
  6. 2.5MFY2026

By type

  1. Grants$2.5M100%

Top programs

  1. 93.855 · Allergy and Infectious Diseases Research$1.3M51%
  2. 93.395 · Cancer Treatment Research$660.8K26%
  3. 93.837 · Cardiovascular Diseases Research$315.1K12%
  4. 93.867 · Vision Research$277.1K11%

Awarding agencies

  1. National Institutes of Health$2.5M100%
    Department of Health and Human Services

Largest awards

  1. DEVELOPMENT OF A SHELF-STABLE UNIVERSAL MUCOSAL HA-VACCINE FOR THE PREVENTION OF INFLUENZA - PROJECT SUMMARY TFF PHARMACEUTICALS (TFFP) IS…$2.8M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Jul 3, 2023 – Sep 22, 2026· R44AI174337
  2. DEVELOPMENT OF DERMAL TARGETING FORMULATIONS FOR SQUAMOUS CELL CARCINOMA - CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) IS AMONG THE MOST…$660.8K
    93.395 · Cancer Treatment Research· National Institutes of Health· Project grant· Sep 17, 2026 – Sep 17, 2026· R44CA257783
  3. DRY POWDERS OF WHOLE BLOOD PREPARED BY THIN-FILM FREEZE-DRYING - BLOOD TRANSFUSIONS ARE THE MOST OFTEN USED LIFE-SAVING PROCEDURE IN…$315.1K
    93.837 · Cardiovascular Diseases Research· National Institutes of Health· Project grant· Aug 28, 2026 – Aug 28, 2026· R41HL186958
  4. COMBINED AMIKACIN AND AZITHROMYCIN IN AN INHALED FORMULATION FOR THE TREATMENT OF NTM - THOUGH IMPORTANT PROGRESSES HAVE BEEN MADE IN THE…$314.4K
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Sep 18, 2025 – Jul 7, 2026· R41AI195081
  5. MICRONEEDLE-BASED MRNA FLU VACCINE FOR TRANSCUTANEOUS IMMUNIZATION - FLU IS A CONTAGIOUS RESPIRATORY DISEASE CAUSED BY INFLUENZA VIRUSES…$314.4K
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Sep 11, 2025 – Jul 7, 2026· R41AI195038
  6. DEVELOPMENT OF MACROPHAGE TARGETING INHALED TIGECYCLINE DRY POWDER FORMULATION FOR TREATING NON-TUBERCULOUS MYCOBACTERIAL (NTM) INFECTIONS…$313.7K
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Sep 9, 2026 – Sep 9, 2026· R43AI197715

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 8, 2026, loaded Oct 8, 2026 · FY2021–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 9, 2026, loaded Oct 9, 2026.